Holen Sie sich die Stockscreener-App
10.56
6.56%
0.65
Handel nachbörslich:
10.56
Schlusskurs vom Vortag:
$9.91
Offen:
$10.21
24-Stunden-Volumen:
831.51K
Relative Volume:
2.33
Marktkapitalisierung:
$711.41M
Einnahmen:
$568.09M
Nettoeinkommen (Verlust:
$27.27M
KGV:
32.23
EPS:
0.3276
Netto-Cashflow:
$71.41M
1W Leistung:
+15.54%
1M Leistung:
+22.51%
6M Leistung:
+52.38%
1J Leistung:
+36.43%
1-Tages-Spanne:
$10.12
$10.57
1-Wochen-Bereich:
$8.915
$10.57
52-Wochen-Spanne:
$5.81
$10.57
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
10.56 | 667.62M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | CJS Securities | Market Outperform |
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Unaccepted RSU grant corrected for Bioventus (NASDAQ: BVS) director - Stock Titan
Bioventus (BVS) director amends filing on unaccepted 9,000 RSU grant - Stock Titan
Bioventus (BVS) CFO exercises 13,000 RSUs and withholds 5,648 shares for tax - Stock Titan
[Form 4] Bioventus Inc. Insider Trading Activity - Stock Titan
Bioventus (BVS) SVP gains 9,925 shares from RSU vesting, with tax withholding - Stock Titan
Bioventus (NASDAQ:BVS) Hits New 1-Year HighWhat's Next? - MarketBeat
(BVS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Are Investors Undervaluing Bioventus (BVS) Right Now? - Yahoo Finance
Aug Movers: Is Bioventus Inc stock showing strong momentumRecession Risk & AI Forecast for Swing Trade Picks - baoquankhu1.vn
JPMorgan Chase Trims Stake in Bioventus Inc. - National Today
JPMorgan Chase & Co. Cuts Stock Position in Bioventus Inc. $BVS - MarketBeat
Bone Growth Stimulator Market size to exceed $2.83 Billion - openPR.com
Momentum Shift: Is Bioventus Inc stock showing strong momentum2026 Market Outlook & AI Driven Stock Reports - baoquankhu1.vn
Stop Loss: Is Bioventus Inc exposed to currency risksEarnings Risk Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Bioventus Inc. (NASDAQ:BVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Investor Mood: Is Bioventus Inc exposed to currency risksWeekly Profit Recap & Safe Capital Growth Tips - baoquankhu1.vn
BVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
BVS Should I Buy - Intellectia AI
BVS.O PE Ratio & Valuation, Is BVS.O Overvalued - Intellectia AI
BVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BVS News & Events - Intellectia AI
(BVS) Risk Channels and Responsive Allocation - Stock Traders Daily
Surprises Report: Is Bioventus Inc in a bullish channel2026 Gainers & Daily Technical Stock Forecast Reports - baoquankhu1.vn
BVS PE Ratio & Valuation, Is BVS Overvalued - Intellectia AI
CJS Securities Initiates Coverage on Bioventus (NASDAQ:BVS) - Defense World
BVS Technical Analysis & ETF Price Forecast - Intellectia AI
Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes - Stock Titan
(BVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Bioventus Inc.(NasdaqGS: BVS) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
BVS Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Aug Wrap: Does Bioventus Inc offer margin of safetyEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Barrington Research initiates coverage of Bioventus (BVS) with outperform recommendation - MSN
Does Bioventus Inc have a competitive edge2026 Buyback Activity & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards - Stock Titan
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards - Stock Titan
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards - Stock Titan
Travel Stocks: Is Bioventus Inc attractive for institutional investors2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Bioventus : Corporate PresentationMarch 2026 - marketscreener.com
Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS - MarketBeat
Insider Sell: Michelle Mcmurry-heath Sells 12,000 Shares of Biov - GuruFocus
Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares - MarketBeat
Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan
Bioventus Receives Consensus Buy Rating from Analysts - National Today
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - MSN
Bioventus stock delivers 63% return after Fair Value signal By Investing.com - Investing.com Australia
Bioventus stock delivers 63% return after Fair Value signal - Investing.com India
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence - GlobeNewswire Inc.
BVS (NASDAQ: BVS) files Form 144 for 12,000 Class A shares via Fidelity - Stock Titan
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.40%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):